Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach (Jun 17, 2017)

Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach is organized by Rockpointe Corporation and would be held on Jun 17, 2017 at Diplomat Resort & Spa Hollywood, Hollywood, Florida, United States Of America.

This activity is intended for dermatologists, dermatology nurse practitioners/physician assistants, allergists, and other clinicians involved in the management of atopic dermatitis (AD). This CME Conference has been approved with a maximum of 1.0 AMA PRA Category 1 Credits.

Although atopic dermatitis (AD) is 2 to 3 times more prevalent than psoriasis, there have not been significant improvements in the management of this serious condition for decades. Patients and providers are dissatisfied and frustrated with the poor efficacy of topical agents and adverse events associated with broad-spectrum immunosuppressants.

An improved understanding of AD pathogenesis has led to the development of new treatments that target the Th2-polarized immune system, which plays a key role in the symptoms of AD and progression of the atopic march to more severe skin disease and respiratory allergic conditions. A new proactive, evidence-based, immunologically founded treatment approach allows patients to be more in control of their disease and actively involved in its management.

This CME activity will help allergists and dermatologists become more familiar with new treatment options for AD, and will discuss how emerging biomarkers in AD have the potential to enhance individualization of therapy, by targeting a patient's specific biological signatures, and help predict and monitor therapeutic response. Clinicians will be provided with strategies to educate their patients, facilitate acceptance of therapies, promote self-management, achieve disease control and ultimately prevent patients from progressing along the atopic march.